At AACR, Experts Discuss Benefits and Challenges of Incorporating NGS in Clinical Trials | GenomeWeb

SAN DIEGO — Incorporating next-generation sequencing in the context of oncology clinical trials has many potential benefits as well as hurdles, according to a number of researchers that presented this week at the American Association for Cancer Research meeting in San Diego.

Researchers are starting to use sequencing both retrospectively to analyze exceptional responders to drugs — a strategy that can be employed to rescue failed trials — and also prospectively to match patients to a specific arm of a trial based on their mutational profile.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.

Sponsored by
Personal Genome Diagnostics

This webinar will highlight the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 


Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.